Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH, Pawlyn C, Cairns DA, de Tute RM, Hockaday A, Collett C, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Rocci A, Snowden JA, Jenner MW, Cook G, Russell NH, Drayson MT, Gregory WM, Kaiser MF, Owen RG, Davies FE, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group.
Jackson GH, et al. Among authors: garg m.
PLoS Med. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454. eCollection 2021 Jan.
PLoS Med. 2021.
PMID: 33428632
Free PMC article.
Clinical Trial.